15.06.20: Not intended for U.S. and UK Media

Bayer extends clinical development program for finerenone with Phase III study in patients with heart failure and preserved ejection fractionFINEARTS-HF is the first large-scale, long-term study to investigate the non-steroidal, selective mineralocorticoid receptor antagonist finerenone on morbidity and mortality outcomes in a heart failure patient populationmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news